Cereno will present the abstract “CS585 is a first-in-class compound targeting the IP receptor for prevention of thrombosis without increased risk of bleeding” at the EHA 2022 Hybrid Congress in Vienna, Austria, on June 9-12, 2022.
It will be presented by Dr. Michael Holinstat, lead of Cereno’s preclinical development programs at University of Michigan and Director of Translational Research at Cereno.